** = Publications listed in SCI/SSCI/Pubmed
** Wolf, S; Madanchi, M; Turko, P; Hollmén, M; Tugues, S; von, Atzigen, J; Giovanoli, P; Dummer, R; Lindenblatt, N; Halin, C; Detmar, M; Levesque, M; Gousopoulos, E
Anti-CTLA4 treatment reduces lymphedema risk potentially through a systemic expansion of the FOXP3+ Treg population.
Nat Commun. 2024; 15(1): 10784
Doi: 10.1038/s41467-024-55002-6
[OPEN ACCESS]
PubMed
FullText
FullText_MUG